Conversely, it has been shown that K-Ras mutation induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas [15] and that PI3K pathway activation mediates resistance to MEK inhibitors in K-ras mutant cancers [16]. Here, KRAS is linked to pancreatic ductal adenocarcinoma.